KẾT QUẢ BƯỚC ĐẦU ĐIỀU TRỊ HÓA XẠ ĐỒNG THỜI CÓ CỦNG CỐ BẰNG DURVALUMAB BỆNH NHÂN UNG THƯ PHỔI KHÔNG TẾ BÀO NHỎ GIAI ĐOẠN IIIB TẠI BỆNH VIỆN K

Abstract

Objective: To evaluate the preliminary outcomes and safety of concurrent chemoradiotherapy (CCRT) followed by Durvalumab consolidation in patients with stage IIIB unresectable non-small cell lung cancer (NSCLC) at K Hospital. Subjects and Methods: A retrospective descriptive study with longitudinal follow-up was conducted on 54 patients with stage IIIB non-small cell lung cancer (NSCLC), treated with concurrent chemoradiotherapy followed by Durvalumab consolidation at K Hospital from 2021 to 2025. Results: Among the 54 patients included in the study, the mean age was 61 ± 9.7 years. The majority had an ECOG performance status of 0–1 (96.3%) and non-squamous histology (87.0%). Following concurrent chemoradiotherapy, the partial response rate was 64.8%. During the immunotherapy phase, 27.8% of patients achieved stable disease, 18.5% had a partial response, and 38.9% experienced disease progression. The median progression-free survival was 18.7 ± 8.1 months. Most adverse events were mild (grade 1–2), with pneumonitis being the most common (44.4% after chemoradiotherapy and 35.2% during immunotherapy). The rate of severe toxicity was low (7.6%). Conclusion: Concurrent chemoradiotherapy followed by Durvalumab consolidation demonstrated promising initial efficacy and good tolerability in patients with unresectable stage IIIB NSCLC.